Orient Pharma Co (ROCO:4166) Total Receivables: NT$265 Mil (As of Dec. 2025)


ROCO:4166 Orient Pharma Co Ltd ROCO:4166
61 GF Score
Price NT$27.25
GF Value NT$45.16
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Orient Pharma Co Total Receivables?

Orient Pharma Co ROCO:4166 61 Total Receivables is NT$265 Mil as of Dec. 2025. GuruFocus rates ROCO:4166 with a GF Score™ of 61/100 and a GF Value™ of NT$45.16 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Orient Pharma Co's Total Receivables for the quarter that ended in Dec. 2025 was NT$265 Mil.

Orient Pharma Co Total Receivables Related Terms

Orient Pharma Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Orient Pharma Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orient Pharma Co Total Receivables Chart

Orient Pharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 79.90 82.24 187.37 288.38 264.60

Orient Pharma Co Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 288.38 241.36 246.77 250.75 264.60
ROCO:4166
61GF Score
Orient Pharma Co Ltd ROCO:4166
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orient Pharma Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of NT$265 Mil mean?
Orient Pharma Co (ROCO:4166) has a Total Receivables of NT$265 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Orient Pharma Co and its competitors.
Is Orient Pharma Co's Total Receivables too high?
Orient Pharma Co's current Total Receivables is NT$265 Mil. Overall, Orient Pharma Co has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Total Receivables compare to ZTS and UTHR?
Orient Pharma Co's Total Receivables of NT$265 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Orient Pharma Co and its competitors. Orient Pharma Co's current Total Receivables is NT$265 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.16, compared to a current price of NT$27.25 — trading 39.7% below its estimated fair value. The current Total Receivables is NT$265 Mil. Orient Pharma Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Total Receivables is NT$265 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued. The current stock price of NT$27.25 is trading 39.7% below its estimated GF Value™ of NT$45.16. GuruFocus considers Orient Pharma Co to be Significantly Undervalued.

Key valuation signals for ROCO:4166:

  • Total Receivables: NT$265 Mil
  • GF Value™: NT$45.16 vs. price of NT$27.25 (39.7% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orient Pharma Co Business Description

Address No. 8, Kehu 1st Road, Huwei Town, Yunlin County, Central Science Park, Taipei, TWN, 106
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
61GF Score

Get the complete analysis for ROCO:4166

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$27.25
Price
NT$45.16
GF Value